D
David P. Berry
Researcher at Leicester General Hospital
Publications - 135
Citations - 7794
David P. Berry is an academic researcher from Leicester General Hospital. The author has contributed to research in topics: Pancreatic cancer & Colorectal cancer. The author has an hindex of 45, co-authored 135 publications receiving 7314 citations. Previous affiliations of David P. Berry include University of Leicester & University of Nottingham.
Papers
More filters
Journal Article
Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences.
Giuseppe Garcea,David P. Berry,Donald J. L. Jones,Raj Singh,Ashley R. Dennison,Peter B. Farmer,Ricky A. Sharma,William P. Steward,Andreas J. Gescher +8 more
TL;DR: The results suggest that a daily dose of 3.6 g curcumin achieves pharmacologically efficacious levels in the colorectum with negligible distribution ofCurcumin outside the gut.
Journal ArticleDOI
Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration.
Giuseppe Garcea,Donald J. L. Jones,Rajinder Singh,Ashley R. Dennison,Peter B. Farmer,Ricky A. Sharma,William P. Steward,Andreas J. Gescher,David P. Berry +8 more
TL;DR: The results suggest that doses of curcumin required to furnish hepatic levels sufficient to exert pharmacological activity are probably not feasible in humans.
Journal ArticleDOI
Dietary polyphenolic phytochemicals—promising cancer chemopreventive agents in humans? A review of their clinical properties
Sarah C. Thomasset,David P. Berry,Giuseppe Garcea,Timothy H. Marczylo,William P. Steward,Andreas J. Gescher +5 more
TL;DR: A review of pilot studies and trials with a cancer chemoprevention‐related rationale, in which either healthy individuals or patients with premalignant conditions or cancer received polyphenolic phytochemicals is presented.
Journal ArticleDOI
Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics.
Lynne M. Howells,David P. Berry,Peter J Elliott,Eric W. Jacobson,Ethan Hoffmann,Brooke Hegarty,Karen Brown,William P. Steward,Andreas J. Gescher +8 more
TL;DR: A pilot study of SRT501, micronized resveratrol, given as 5.0 g daily for 14 days, to patients with colorectal cancer and hepatic metastases scheduled to undergo hepatectomy found it to be well tolerated and warrants further clinical exploration to assess its potential clinical utility.
Journal ArticleDOI
Radioembolization of Liver Metastases From Colorectal Cancer Using Yttrium-90 Microspheres With Concomitant Systemic Oxaliplatin, Fluorouracil, and Leucovorin Chemotherapy
Ricky A. Sharma,Guy van Hazel,Bruno Morgan,David P. Berry,Keith Blanshard,David H. Price,Geoffrey C. Bower,Jennifer Shannon,Peter Gibbs,William P. Steward +9 more
TL;DR: A phase I study of SIR-Spheres therapy with modified FOLFOX4 systemic chemotherapy in patients with inoperable liver metastases from CRC who had not previously received chemotherapy for metastatic disease concluded that this chemoradiation regime merits evaluation in phase II-III trials.